Regeneron

News

US accuses Regeneron of fraud in Eylea price reporting

The US government has filed a lawsuit against Regeneron, claiming that the company falsely inflated the average sales price for ophthalmology blockbuster Eylea to manipula

News

FDA turns down Regeneron bispecific blood cancer antibody

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).

News

FDA will decide in June on Dupixent for COPD

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

News

Lilly trumpets early success with deafness gene therapy

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness

US accuses Regeneron of fraud in Eylea price reporting

FDA turns down Regeneron bispecific blood cancer antibody

FDA will decide in June on Dupixent for COPD

Regeneron set for August FDA decision on BCMA bispecific

FDA changes its mind and approves Takeda’s Eohilia

Lilly trumpets early success with deafness gene therapy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Regeneron

Editor's Picks